Imaginostics Receives $725k Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) for Clinical Validation of its Biomarkers in Alzheimer’s Disease and Related Dementias
On September 6th, 2022, Imaginostics received a $725,000 investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support its pilot clinical study testing a novel imaging approach that can measure structure and function of the vascular system in the brain.
A significant portion of dementia cases have some aspect of cerebral small vessel disease, but current methods for quantitatively measuring vascular structure and function in living patients are limited. In their study, Imaginostics will collaborate with researchers at Harvard Medical School’s Brigham and Women’s Hospital to use their novel approach in patients with vascular dementia and mild cognitive impairment. If successful, Imaginostics would have a sensitive biomarker that could allow for earlier and more accurate diagnosis, as well as better clinical trial enrollment and outcome measurements of vascular function.
About Imaginostics:
Imaginostics, Inc., is a longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com
This content is solely the responsibility of the author and does not necessarily represent the official views of the Alzheimer’s Drug Discovery Foundation.